Markets

European stocks rise as Novo Nordisk lifts healthcare on Wegovy data

Published Updated
By

European shares edge higher on Monday, supported by healthcare stocks after data showed Danish drugmaker Novo Nordisk’s weight-loss drug Wegovy offered better heart-protective benefits than rival treatments from US-based Eli Lilly.

The pan-European STOXX 600 was up 0.26% at 551.56, as of 0713 GMT, following its first weekly loss in four on Friday.

Healthcare stocks were among top sectoral performers.

Shares of Novo Nordisk, the fourth-largest healthcare company on the STOXX index, climbed 3.1% after the company said Wegovy cut the risk of heart attack, stroke or death by 57% versus Eli Lilly’s rival medicines Mounjaro and Zepbound in a real-world comparison.

Defence stocks gained 1.2%, with Britain’s BAE Systems up 2%, as Norway said it had chosen Britain as its strategic partner for the acquisition of new frigates, in a deal worth some 10 billion pounds ($13.51 billion).

On the other side of the Atlantic, a US appeals court ruled on Friday that most of US President Donald Trump’s tariffs are illegal, although allowed them to remain in place until mid-October to permit further appeals.

Trading is expected to be light throughout the day due to a US holiday.